Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8
Primary Industries
- Medical
- Wound Care
- Supply
- Surgical
- Device
- Puncture
- Sealant
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 3527
License Grant
Licensee wishes to grant Licensor, an individual, a bonus pursuant to Licensee's obligations under its Employment Agreement with Licensor dated April 1, 1999, all upon the terms and conditions set forth.
License Property
The first Myers Patent # 5,486,195 was for the Method and Apparatus for Arteriotomy Closure.
The second Myers Patent # 5,941,897 was for the Energy Activated Fibrin Plug.
The third Myers Patent' shall refer to the U.S. Patent No. 5,725,551.
The second Myers Patent # 5,941,897 was for the Energy Activated Fibrin Plug.
The third Myers Patent' shall refer to the U.S. Patent No. 5,725,551.
The Myers Solution is a puncture closing product and technique that utilizes a human glue deployment to close puncture wounds following surgery, thereby avoiding sutures and limiting discomfort to patients following surgery.
Field of Use
The rights granted apply to puncture wounds.
IPSCIO Record ID: 5234
License Grant
Licensee wishes to grant Licensor, an individual, a bonus pursuant to Licensee's obligations under its Employment Agreement with Licensor dated April 1, 1999, all upon the terms and conditions set forth.
License Property
The first Patent # 5,486,195 was for the Method and Apparatus for Arteriotomy Closure. The second Patent # 5,941,897 was for the Energy Activated Fibrin Plug. The Myers Solution is a puncture closing product and technique that utilizes a human glue deployment to close puncture wounds following surgery, thereby avoiding sutures and limiting discomfort to patients following surgery.
Field of Use
The rights granted apply to puncture wounds.
IPSCIO Record ID: 29043
License Grant
Licensor hereby grants to Licensee a license solely in the Field of Use under Licensed Patents to make, have made, use and sell any Licensed Product and to practice any Licensed Method solely in the Field of Use throughout the Territory.
License Property
The agreement relates to U.S. Pat. No. 5,594,1897, U.S. Pat. No. 5,486,195; and U.S. Pat. No 5,725,551.
Field of Use
FIELDS OF USE, except for and specifically excluding any applications, devices or methods designed to seal arterial puncture sites following angiography, angioplasty and/or other cardiac procedures.
IPSCIO Record ID: 29833
License Grant
This amendment is for increasing the percentage royalty due and to include within the terms of the Royalty Agreement an additional patent.
IPSCIO Record ID: 26781
License Grant
Licensor, who shares an operating officer with Licensee, hereby grants to Licensee a license solely in the Field of Use under Licensed Patents to make, have made, use and sell any Licensed Product and to practice any Licensed Method solely in the Field of Use throughout the Territory. Such license shall be exclusive within the Territory in the Field of Use. All Fields of Use, except for and specifically excluding any applications, devices or methods designed to seal arterial puncture sites following angiography, angioplasty and/or other cardiac procedures.
License Property
This agreement is related to U.S. Pat. No. 5,941,897, U.S. Pat. No. 5,486,195; and U.S. Pat. No 5,725,551.
This is technology where the arteriotomy can be sealed by delivery of a patient specific autologous fibrin glue to a debrided, synthesized area adjacent to the extravascular opening of the arteriotomy.
Field of Use
All FIELDS OF USE, except for and specifically excluding any applications, devices or methods designed to seal arterial puncture sites following angiography, angioplasty and/or other cardiac procedures.
IPSCIO Record ID: 29832
License Grant
This agreement amends the Royalty Agreement to increase the percentage royalty due thereunder and to include within the terms of the Royalty Agreement an additional patent.
IPSCIO Record ID: 5286
License Grant
Under our license agreements, the Licensee has exclusive rights to manufacture, market and distribute all current and future sizes of the patented Angio-Seal for hemostatic puncture closures for cardiovascular use worldwide.
License Property
Angio-Seal(TM) Vascular Closure Device (Angio-Seal) is designed to seal and close femoral artery punctures made during diagnostic and therapeutic cardiovascular catheterizations. The Angio-Seal STS Plus device offers quick, consistent and predictable hemostasis (cessation of bleeding) at the puncture site. Its fast, secure closure reduces the risk of complications and can allow patients to resume activities sooner than if managed with manual compression. The Angio-Seal STS Plus device includes a small bio-resorbable anchor, suture and collagen pad. The anchor is placed in the artery through a small delivery system and secured against the artery's interior wall. Then the collagen pad, which is positioned on the outside of the artery, is bound together with the suture to form a secure seal. The self-tightening suture enables the physician to finalize the closure procedure immediately. Unlike many other vascular closure devices, all components of the Angio-Seal STS Plus device are fully absorbed with 60 to 90 days, so no foreign material permanently remains in the body. The angio-Seal STS plus platform is composed of an absorbable collagen sponge and a specially designed absorbable polymer anchor connected by an absorbable self-tightening suture. The device seals and sandwiches the arteriotomy between its two primary components, the anchor and the collagen sponge. Hemostasis is achieved primarily through mechanical means and is supplemented by the platelet inducing properties of the collagen.
Field of Use
The rights granted apply for hemostatic puncture closures for cardiovascular use.
IPSCIO Record ID: 5279
License Grant
The Companies desire to enter into an agreement and licenses to settle the Minnesota Action and the Minnesota Counterclaims upon the terms and conditions set forth herein.
License Property
Licensed Product shall mean any vascular closure device (U.S. Patent No. 5,275,616 (the ‘616 patent), U.S. Patent No. B1 5,275,616, reexamination certificate, (the B1 ‘616 patent), U.S. Patent No. 5,591,205 (the‘205 patent), U.S. Patent No. 5,601,602 (the ‘602 patent), and U.S. Patent No. 5,716,375).
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
